Wells Fargo Raises Zimmer Biomet Rating, Citing Monogram Robot

Wells Fargo upgraded Zimmer Biomet to Overweight, citing the FDA-cleared Monogram robot's revenue potential. The system was acquired in a $177M 2025 deal.

Original reporting
Published Nov 18, 2026, 6:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 7:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo Raises Zimmer Biomet Rating, Citing Monogram Robot — source image
Decision brief

The 30-second read

$ZBHBullishHigh
01

Why it matters

The FDA clearance validates the product and supports the analyst's rating upgrade, likely prompting buying interest.

02

Market read

Analyst upgrade combined with regulatory approval creates a fresh catalyst for ZBH, making it a short‑term buying opportunity.

03

What to watch

Potential competition from other robotic surgery platforms could temper long‑term upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Zimmer Biomet acquired Monogram Technologies in 2025 for $177 million; the Monogram system is a semi‑autonomous robot for orthopedic procedures.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Wells Fargo upgraded Zimmer Biomet to Overweight after FDA cleared its Monogram robot, indicating new revenue potential.

Expected impact

likely upward pressure as investors price in the rating upgrade and regulatory approval

Evidence & confidence

The upgrade is a fresh, material catalyst; FDA clearance adds tangible growth upside.

Market effects

May boost sentiment for orthopedic device makers and related medtech stocks.

U.S. medtech sector could see modest gains.

Limited to investors tracking U.S. medical device equities.

Counterpoint

If the market has already priced in the clearance, the upgrade may be a short‑term bump only.

Key entities

  • Zimmer Biomet

    Medical device manufacturer.

  • Wells Fargo

    Equity research firm that raised the rating.

Related articles

$ZBHMed

Zimmer submits Monogram robot to FDA

Zimmer Biomet submitted its autonomous Monogram robot for FDA clearance, aiming for approval in 2027. The company acquired Monogram in 2025 for $177M. Clinical trials showed no safety events, with potential time savings and accuracy improvements. CEO Ivan Tornos expects FDA review may involve back-and-forth due to the technology's novelty.

$ZBHMed

Why is Zimmer Biomet stock climbing today?

Zimmer Biomet (ZBH) stock rose 1.8% after Wells Fargo upgraded it to Overweight with a $123 price target, citing the upcoming Monogram robotic system launch. Stifel raised its target to $140, while BMO lowered its target to $101. The stock gained despite broader market declines, reaching an intraday high of $104.28.

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.